Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company was founded in October 2017 and is headquartered in Watertown, MA.
相关临床试验
12
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
16.7%
Available
1
8.3%
已完成
4
33.3%
Enrolling By Invitation
1
8.3%
招募中
4
33.3%
暂无批准数据
- Disc Medicine presented initial Phase 2 RESTORE-PV results showing DISC-3405 raised hepcidin and lowered serum iron in patients with polycythemia vera. - Among 13 Cohort A patients completing 26 weeks, mean phlebotomy events fell from 4.0 at baseline to 0.6 post-treatment (p<0.0001). - Mean hematocrit stayed below 45% through week 26 with initial symptom improvement, and the drug was generally well tolerated. - DISC-3405 is the first anti-TMPRSS6 monoclonal antibody to demonstrate phlebotomy reduction in polycythemia vera, with further data expected by end of 2026.
- Incyte received Buy ratings from multiple analysts including Stifel Nicolaus with a $123 price target and Argus Research with a $115 target, reflecting confidence in the pharmaceutical company's prospects. - The company reported strong Q1 2024 financial results with quarterly revenue of $1.27 billion and net profit of $303.33 million, representing significant growth from the prior year period. - Despite positive analyst sentiment, corporate insider activity shows negative sentiment with 99 insiders increasing share sales, including President Pablo Cagnoni's $1.8 million stock sale. - Analyst consensus maintains a Moderate Buy rating with an average price target of $108.06, suggesting 13.43% upside potential from current trading levels.
- Replimune Group laid off more than 200 Massachusetts employees after the FDA rejected its melanoma treatment RP1 for the second time, citing inadequate clinical trial design. - The company's IGNYTE trial showed a 34% response rate with nearly two-year median response duration for RP1 combined with nivolumab in advanced melanoma patients. - CEO Sushil Patel criticized the regulatory system, stating the treatment was needed by patients and failed due to systemic issues rather than drug efficacy. - The layoffs affect employees across all functions at the Woburn headquarters and Framingham manufacturing facility, representing a significant portion of the company's 480-person Massachusetts workforce.
- Disc Medicine shares dropped 11.5% following reports that FDA biologics director Vinay Prasad expressed skepticism about bitopertin's efficacy for treating porphyria. - The drug is under review through the FDA's Commissioner's National Priority Voucher program, which aims to reduce assessment times to one to two months. - Wall Street analysts dismissed the concerns as overblown, maintaining positive ratings while noting Disc management was "blindsided" by the report. - Disc Medicine expects potential approval by the end of January 2026 for treating erythropoietic protoporphyria in patients aged 12 years and older.
- Disc Medicine reported positive initial data from the RALLY-MF Phase 2 trial of DISC-0974, demonstrating meaningful anemia responses across all patient subgroups with myelofibrosis regardless of baseline transfusion status. - The treatment achieved substantial reductions in hepcidin levels exceeding 75% from baseline and corresponding increases in serum iron, with 63% of non-transfusion dependent patients achieving hemoglobin increases of ≥1 g/dL for ≥12 weeks. - DISC-0974 showed efficacy independent of concomitant JAK inhibitor therapy use, with 71% of low transfusion burden patients achieving transfusion independence over a 16-week period. - The drug was generally well-tolerated with only diarrhea and urinary tract infections reported as treatment-related adverse events in two or more subjects.
- Disc Medicine will present initial data from the RALLY-MF Phase 2 trial of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia at the 67th ASH Annual Meeting in December 2025. - The study evaluates DISC-0974 both as monotherapy and in combination with JAK inhibitor backbone therapies including ruxolitinib and momelotinib across a range of myelofibrosis anemia patients. - The company will also present data on DISC-3405 for polycythemia vera and expects initial readouts for DISC-3405 trials in polycythemia vera and sickle cell disease in 2026. - Management will host a call during ASH on December 7 to review the presented data and discuss next steps in development for their hematologic disease portfolio.
- Disc Medicine will present data from multiple hematology programs at the European Hematology Association 2025 Congress, including long-term extension trial results for bitopertin in erythropoietic protoporphyria. - The company will showcase additional durability data from Phase 1b studies of DISC-0974 in myelofibrosis anemia patients and new data from DISC-3405 studies in healthy volunteers. - Management plans to host a corporate update conference call on June 16 to review the presented data as the company progresses toward major milestones in the second half of 2025.
- Disc Medicine has initiated the APOLLO confirmatory trial for bitopertin in erythropoietic protoporphyria (EPP) and remains on track to submit an NDA under accelerated approval pathway in the second half of 2025. - The company is advancing its hematologic disease pipeline with DISC-0974 studies in myelofibrosis and chronic kidney disease anemia, with data readouts expected in H2 2025. - Following a successful $259 million public offering in January, Disc Medicine reports a strong financial position with $695 million in cash, providing runway into 2028.
• Gemini Therapeutics has successfully concluded a Type C meeting with the FDA, reaching agreement on the design of APOLLO confirmatory trial for bitopertin in EPP and XLP treatment. • The planned APOLLO trial will enroll approximately 150 patients across multiple continents in a randomized, double-blind, placebo-controlled study with a 1:1 allocation ratio. • The company aims to submit a New Drug Application for bitopertin under the Accelerated Approval Program in the second half of 2025, with trial initiation planned for mid-2025.
- Disc Medicine is preparing for an NDA submission for bitopertin in erythropoietic protoporphyria (EPP) following positive FDA feedback, potentially leading to accelerated approval. - Phase 2 trials for DISC-0974 in anemia of myelofibrosis (MF) and chronic kidney disease (CKD) are progressing, with initial data expected in the second half of 2025. - A Phase 2 study of DISC-3405 in polycythemia vera (PV) is set to begin in H1 2025, expanding Disc Medicine's portfolio in hematologic diseases. - Disc Medicine's strengthened financial position, with a cash runway into 2027, supports the advancement of its clinical programs and strategic objectives.
